Anal canal cancer

Summary

Anal canal cancer (MONDO:0000405) is a cancer and 18 clinical trials. Top therapeutic interventions include cisplatin. A subtype of intestinal cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anal canal cancer
Mondo ID	MONDO:0000405
DOID	DOID:0050688
ICD-10-CM	C21.1
ICD-11	655574575
SNOMED CT	363352004
UMLS	C0153445
MedGen	509296
Anatomy (UBERON)	UBERON:0000159
Is cancer (heuristic)	yes

Also known as: anal canal cancer · cancer of anal canal · malignant anal canal neoplasm · malignant neoplasm of anal canal

Disease family

This is a subtype of intestinal cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › intestinal cancer › anal canal cancer

Related subtypes (5): small intestine cancer, intestine carcinoma in situ, gastric intestinal type adenocarcinoma, colorectal cancer, colorectal Kaposi sarcoma

Subtypes (1): anal canal carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	10
Not specified	7
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05374252	PHASE3	UNKNOWN	Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
NCT02185443	PHASE2	RECRUITING	Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
NCT02701088	PHASE2	ACTIVE_NOT_RECRUITING	Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life
NCT03403465	PHASE2	ACTIVE_NOT_RECRUITING	Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
NCT05040815	PHASE2	RECRUITING	Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer
NCT06640283	PHASE2	RECRUITING	Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
NCT00754078	PHASE2	UNKNOWN	A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy
NCT02437851	PHASE2	COMPLETED	Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
NCT02560298	PHASE2	UNKNOWN	Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
NCT03946358	PHASE2	COMPLETED	Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
NCT05060471	PHASE2	COMPLETED	PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
NCT06630793	Not specified	RECRUITING	IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer
NCT07059442	Not specified	NOT_YET_RECRUITING	Screening for Anal Cancer and Precancer in Women With HIV (SANCA)
NCT01325961	Not specified	COMPLETED	Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers
NCT01845779	Not specified	COMPLETED	Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal
NCT03465501	Not specified	COMPLETED	Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates
NCT03731754	Not specified	UNKNOWN	Cross Closure for Reconstructing the Perineal Wound of Abdominoperineal Resection
NCT03942900	Not specified	WITHDRAWN	Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	1